The alpha2-adrenoceptor selectivity of dexmedetomidine is dose-dependent. At low to medium doses or at slow rates of infusion, high levels of alpha2-adrenoceptor selectivity are observed, while high doses or rapid infusions of low doses are associated with both alpha1 and alpha2 activities. Thirty cases in each group were recruited for the study and were randomized to receive Ropivacaine alone or Ropivacaine with Dexmedetomidine. A pilot study was conducted to arrive at the actual mean differences, and the outcome parameters being studied with the visual analogue scale (VAS), Modified Bromage score and mean time for first analgesic requirement. Randomization was done based on computer generated randomization method. There was no statistically significant difference in mean MBS between both the groups at baseline (p=1.0), 10 minutes (p=0.897), 30 minutes (p=1.0), 45 minutes (p=1.0), 30 minutes (p=0.050), 45 minutes (p=1.0), 60 minutes (p=1.0), 75 minutes (p=1.0), 90 minutes (p=1.0), 105 minutes (p=1.0), 120 minutes (p=1.0) and 180 minutes (p=1.0). There was a statistically significant difference at 5 minutes (p=0.046) and from 240 minutes and thereafter (p<0.05) during follow up. Dexmedetomidine group had lower VAS compared to the control group.